The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Mouse Models of Tumor Development in Neurofibromatosis Type 1
Abstract
Neurofibromatosis type 1 (NF1) is a prevalent familial cancer syndrome resulting from germ line mutations in the NF1 tumor suppressor gene. Hallmark features of the disease are the development of benign peripheral nerve sheath tumors (neurofibromas), which can progress to malignancy. Unlike humans, mice that are heterozygous for a mutation in Nf1 do not develop neurofibromas. However, as described here, chimeric mice composed in part of Nf1−/−cells do, which demonstrates that loss of the wild-type Nf1 allele is rate-limiting in tumor formation. In addition, mice that carry linked germ line mutations in Nf1 and p53 develop malignant peripheral nerve sheath tumors (MPNSTs), which supports a cooperative and causal role for p53 mutations in MPNST development. These two mouse models provide the means to address fundamental aspects of disease development and to test therapeutic strategies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a
Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D., & Lowe, S. W. (1997) · Cell · doi:10.1016/s0092-8674(00)81902-9 · Cited by 5,218
Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours
Donehower, L. A., Harvey, M., Slagle, B. L., McArthur, M. J., Montgomery, C. A., Butel, J. S., & Bradley, A. (1992) · Nature · doi:10.1038/356215a0 · Cited by 4,649
Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis.
Greenblatt, M. S., Bennett, W. P., Hollstein, M., & Harris, C. C. (1994) · PubMed · Cited by 3,463
Type 1 Neurofibromatosis Gene: Identification of a Large Transcript Disrupted in Three NF1 Patients
Wallace, M. R., Marchuk, D. A., Andersen, L. B., Letcher, R., Odeh, H. M., Saulino, A. M., Fountain, J. W., Brereton, A., Nicholson, J., Mitchell, A. L., et al. (1990) · Science · doi:10.1126/science.2134734 · Cited by 1,475
Neurofibromatosis. Conference statement, National Institute of Health development conference
Stumpf, D. A. (1988) · JAMA Neurology · Cited by 1,236
Cawthon, R. M., Weiss, R., Xu, G., Viskochil, D., Culver, M., Stevens, J., Robertson, M., Dunn, D., Gesteland, R., O'Connell, P., et al. (1990) · Cell · doi:10.1016/0092-8674(90)90253-b · Cited by 1,094
Deletions and a translocation interrupt a cloned gene at the neurofibromatosis type 1 locus
Viskochil, D., Buchberg, A. M., Xu, G., Cawthon, R. M., Stevens, J., Wolff, R. K., Culver, M., Carey, J. C., Copeland, N. G., Jenkins, N. A., et al. (1990) · Cell · doi:10.1016/0092-8674(90)90252-a · Cited by 1,082
The GAP-related domain of the neurofibromatosis type 1 gene product interacts with ras p21
Martin, G. A., Viskoohil, D., Bollag, G., McCabe, P. C., Crosier, W. J., Haubruck, H., Conroy, L., Clark, R., O'Connell, P., Cawthon, R. M., et al. (1990) · Cell · doi:10.1016/0092-8674(90)90150-d · Cited by 982
Lin, A. W., Barradas, M., Stone, J. C., van Aelst, L., Serrano, M., & Lowe, S. W. (1998) · Genes & Development · doi:10.1101/gad.12.19.3008 · Cited by 945
Neurofibromatosis, Phenotype, Natural History, and Pathogenesis
Riccardi, V. M., & Smirniotopoulos, J. (1992) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199211000-00009 · Cited by 893
Cited by
Chromosomal Instability and Tumors Promoted by DNA Hypomethylation
Eden, A., Gaudet, F., Waghmare, A., & Jaenisch, R. (2003) · Science · doi:10.1126/science.1083557 · Cited by 1,399
Modelling the molecular circuitry of cancer
Hahn, W. C., & Weinberg, R. A. (2002) · Nature Reviews Cancer · doi:10.1038/nrc795 · Cited by 944
Gutmann, D. H., Ferner, R. E., Listernick, R. H., Korf, B. R., Wolters, P. L., & Johnson, K. J. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.4 · Cited by 862
Maximizing mouse cancer models
Frese, K. K., & Tuveson, D. A. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2192 · Cited by 717
Neurofibromas in NF1: Schwann Cell Origin and Role of Tumor Environment
Zhu, Y., Ghosh, P., Charnay, P., Burns, D. K., & Parada, L. F. (2002) · Science · doi:10.1126/science.1068452 · Cited by 633
Neurofibromatosis type 1: a multidisciplinary approach to care
Hirbe, A. C., & Gutmann, D. H. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70063-8 · Cited by 626
Germline gain-of-function mutations in SOS1 cause Noonan syndrome
Roberts, A. E., Araki, T., Swanson, K. D., Montgomery, K. T., Schiripo, T. A., Joshi, V. A., Li, L., Yassin, Y., Tamburino, A. M., Neel, B. G., et al. (2007) · Nature Genetics · doi:10.1038/ng1926 · Cited by 605
NF1 Tumor Suppressor Gene Function
Cichowski, K., & Jacks, T. (2001) · Cell · doi:10.1016/s0092-8674(01)00245-8 · Cited by 601
Self-citationThe NF1 tumor suppressor critically regulates TSC2 and mTOR
Johannessen, C. M., Reczek, E. E., James, M. F., Brems, H., Legius, E., & Cichowski, K. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0503224102 · Cited by 601
Self-citationtp53 mutant zebrafish develop malignant peripheral nerve sheath tumors
Berghmans, S., Murphey, R. D., Wienholds, E., Neuberg, D., Kutok, J. L., Fletcher, C. D. M., Morris, J. P., Liu, T. X., Schulte-Merker, S., Kanki, J. P., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0406252102 · Cited by 597
Zhu, Y., Guignard, F., Zhao, D., Liu, L., Burns, D. K., Mason, R. P., Messing, A., & Parada, L. F. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.07.004 · Cited by 550
Neurofibromatosis 1 and neurofibromatosis 2: a twenty first century perspective
Ferner, R. E. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70075-3 · Cited by 511
A RASopathy gene commonly mutated in cancer: the neurofibromatosis type 1 tumour suppressor
Ratner, N., & Miller, S. J. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3911 · Cited by 493
PRC2 loss amplifies Ras-driven transcription and confers sensitivity to BRD4-based therapies
De Raedt, T., Beert, E., Pasmant, E., Luscan, A., Brems, H., Ortonne, N., Helin, K., Hornick, J. L., Mautner, V., Kehrer-Sawatzki, H., et al. (2014) · Nature · doi:10.1038/nature13561 · Cited by 461
Self-citationNf1;Trp53 mutant mice develop glioblastoma with evidence of strain-specific effects
Reilly, K. M., Loisel, D. A., Bronson, R. T., McLaughlin, M. E., & Jacks, T. (2000) · Nature Genetics · doi:10.1038/79075 · Cited by 425
Self-citationMany Ribosomal Protein Genes Are Cancer Genes in Zebrafish
Amsterdam, A., Sadler, K. C., Lai, K., Farrington, S., Bronson, R. T., Lees, J. A., & Hopkins, N. (2004) · PLoS Biology · doi:10.1371/journal.pbio.0020139 · Cited by 417
Self-citationMolecular neurobiology of mTOR
Switon, K., Kotulska, K., Janusz-Kaminska, A., Zmorzynska, J., & Jaworski, J. (2017) · Neuroscience · doi:10.1016/j.neuroscience.2016.11.017 · Cited by 387
Mouse Tumor Model for Neurofibromatosis Type 1
Vogel, K. S., Klesse, L. J., Velasco-Miguel, S., Meyers, K., Rushing, E. J., & Parada, L. F. (1999) · Science · doi:10.1126/science.286.5447.2176 · Cited by 372
Cancer Modeling in the Modern Era
Van Dyke, T., & Jacks, T. (2002) · Cell · doi:10.1016/s0092-8674(02)00621-9 · Cited by 358
Self-citationMalignant Peripheral Nerve Sheath Tumors
Farid, M., Demicco, E. G., Garcia, R., Ahn, L., Merola, P. R., Cioffi, A., & Maki, R. G. (2014) · The Oncologist · doi:10.1634/theoncologist.2013-0328 · Cited by 354
Mechanisms in the pathogenesis of malignant tumours in neurofibromatosis type 1
Brems, H., Beert, E., de Ravel, T., & Legius, E. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70033-6 · Cited by 349
The Molecular and Genetic Basis of Neurological Tumours
Zhu, Y., & Parada, L. F. (2002) · Nature Reviews Cancer · doi:10.1038/nrc866 · Cited by 309
Casey, M., Vaughan, C. J., He, J., Hatcher, C. J., Winter, J. M., Weremowicz, S., Montgomery, K., Kucherlapati, R., Morton, C. C., & Basson, C. T. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10841 · Cited by 281
Kolberg, M., Holand, M., Agesen, T. H., Brekke, H. R., Liestol, K., Hall, K. S., Mertens, F., Picci, P., Smeland, S., & Lothe, R. A. (2013) · Neuro-Oncology · doi:10.1093/neuonc/nos287 · Cited by 270
Exploiting cancer cell vulnerabilities to develop a combination therapy for ras-driven tumors
De Raedt, T., Walton, Z., Yecies, J. L., Li, D., Chen, Y., Malone, C. F., Maertens, O., Jeong, S. M., Bronson, R. T., Lebleu, V., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.08.014 · Cited by 258
Self-citationERKs in cancer: friends or foes?
Deschênes-Simard, X., Kottakis, F., Meloche, S., & Ferbeyre, G. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-2381 · Cited by 186
Lévy, P., Ripoche, H., Laurendeau, I., Lazar, V., Ortonne, N., Parfait, B., Leroy, K., Wechsler, J., Salmon, I., Wolkenstein, P., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0182 · Cited by 53
Losses in chromosomes 17, 19, and 22q in neurofibromatosis type 1 and sporadic neurofibromas
Koga, T., Iwasaki, H., Ishiguro, M., Matsuzaki, A., & Kikuchi, M. (2002) · Cancer Genetics and Cytogenetics · doi:10.1016/s0165-4608(02)00527-7 · Cited by 35
Metadata
- Authors
- Cichowski, K., Shih, T. S., Schmitt, E., Santiago, S., Reilly, K., McLaughlin, M. E., Bronson, R. T., & Jacks, T.
- Venue
- Science
- Published
- 1999-12-10
- Volume
- 286
- Issue
- 5447
- Pages
- 2172-2176
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2055729102
- Cited by
- 467
- References
- 34
- FWCI
- 15.33
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.